This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Eli Lilly Halts Alzheimer's Drug Trial

INDIANAPOLIS ( TheStreet) -- Eli Lilly (LLY - Get Report) was forced to halt development of an experimental Alzheimer's disease drug after an early look at results from two late-stage clinical trials determined the drug to be ineffective.

Lilly shares fell 2% to $34.75 in Tuesday's pre-market trading on news of the setback for the Alzheimer's drug semagacestat, one of two drugs being in the company's pipeline that are in late-stage studies against the neuro-degenerative disease.

The failure of semagacestat will also heighten concerns about Lilly's future growth given the looming loss of patent protection through 2014 on drugs that presently account for 60% of the company's revenue.

Tuesday, Lilly said it would take a charge of 3-4 cents a share in the third quarter to account for the halting of the semagacestat clinical trials. The company reiterated 2010 guidance of $4.44 to $4.59 a share on a reported basis.

The two phase III clinical trials of semagacestat enrolled more than 2,600 patients with mild to moderate Alzheimer's, randomizing them to treatment with semagacestat or a placebo. An interim analysis of the studies found that semagacestat-treated patients were performing worse on tests of cognition and ability to complete daily living tasks compared to patients treated with a placebo. In addition, semagacestat patients were at a higher risk for developing skin cancer.

Lilly said Tuesday that phase III trials involving the company's other late-stage Alzheimer's drug solanezumab are continuing.

Both semagacestat and solanezumab are designed to reduce the levels of amyloid beta plaques, protein substances that attach to and destroy neurons in the brain. Amyloid beta is thought to one of the causes of Alzheimer's.

Semagacestat works by inhibiting an enzyme, gamma secretase, which the body uses to form amyloid beta plaques.

Earlier this year, Pfizer (PFE - Get Report) and Medivation (MDVN - Get Report) said a phase III study of their Alzheimer's drug Dimebon also failed, although additional clinical trials of that drug continue.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MDVN $42.28 1.44%
LLY $82.04 -1.92%
PFE $32.77 -0.06%
AAPL $118.30 0.42%
FB $104.24 -1.15%


Chart of I:DJI
DOW 17,719.92 -78.57 -0.44%
S&P 500 2,080.41 -9.70 -0.46%
NASDAQ 5,108.6660 -18.8590 -0.37%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs